Global Pulmonary Arterial Hypertension (PAH) Market Growth (Status and Outlook) 2023-2029

Global Pulmonary Arterial Hypertension (PAH) Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Pulmonary Arterial Hypertension (PAH) Industry Forecast” looks at past sales and reviews total world Pulmonary Arterial Hypertension (PAH) sales in 2022, providing a comprehensive analysis by region and market sector of projected Pulmonary Arterial Hypertension (PAH) sales for 2023 through 2029. With Pulmonary Arterial Hypertension (PAH) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Arterial Hypertension (PAH) industry.

This Insight Report provides a comprehensive analysis of the global Pulmonary Arterial Hypertension (PAH) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Arterial Hypertension (PAH) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pulmonary Arterial Hypertension (PAH) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Arterial Hypertension (PAH) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Arterial Hypertension (PAH).

The global Pulmonary Arterial Hypertension (PAH) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Pulmonary Arterial Hypertension (PAH) players cover Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Arterial Hypertension (PAH) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5

Segmentation by application
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena

Please note: The report will take approximately 2 business days to prepare and deliver.